MUC16 and neoplasm: showed that the monoclonal antibody AR9.6 significantly inhibits the AKT and GSK3β pathways activated by MUC16, effectively reducing tumor growth and metastasis and highlighting AR9.6’s potential as a novel immunotherapeutic approach for MUC16-mediated therapy in pancreatic cancer (65).